Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages JCO.20.02573
Publisher
American Society of Clinical Oncology (ASCO)
Online
2021-04-29
DOI
10.1200/jco.20.02573
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
- (2019) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Liquid biopsy in lymphoma
- (2019) Davide Rossi et al. HAEMATOLOGICA
- Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303
- (2019) Nancy L. Bartlett et al. JOURNAL OF CLINICAL ONCOLOGY
- Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction
- (2019) David M. Kurtz et al. CELL
- Prognostication with circulating tumor DNA: is it ready for prime time?
- (2019) David M. Kurtz Hematology-American Society of Hematology Education Program
- Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review
- (2018) G Iacoboni et al. ANNALS OF ONCOLOGY
- Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma
- (2018) Valeria Spina et al. BLOOD
- Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials
- (2018) Matthew J. Maurer et al. JOURNAL OF CLINICAL ONCOLOGY
- Positron Emission Tomography–Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial
- (2018) Ulrich Dührsen et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
- (2018) David M. Kurtz et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic impact of diagnosis to treatment interval (DTI) in diffuse large B-cell lymphoma patients: a real-life monocentric study
- (2018) Vincent Camus et al. LEUKEMIA & LYMPHOMA
- Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort
- (2018) Elodie Bohers et al. Blood Cancer Journal
- Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non–Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma
- (2017) John P. Leonard et al. JOURNAL OF CLINICAL ONCOLOGY
- Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
- (2017) Umberto Vitolo et al. JOURNAL OF CLINICAL ONCOLOGY
- The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma
- (2017) Clémentine Sarkozy et al. Oncotarget
- Care and Outcomes of Patients With Cancer Admitted to the Hospital on Weekends and Holidays: A Retrospective Cohort Study
- (2016) Lauren Lapointe-Shaw et al. Journal of the National Comprehensive Cancer Network
- Integrated digital error suppression for improved detection of circulating tumor DNA
- (2016) Aaron M Newman et al. NATURE BIOTECHNOLOGY
- Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA
- (2016) F. Scherer et al. Science Translational Medicine
- Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing
- (2015) D. M. Kurtz et al. BLOOD
- Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies
- (2015) David W. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study
- (2015) Mark Roschewski et al. LANCET ONCOLOGY
- Survival Disparities by Insurance Type for Patients Aged 15-64 Years With Non-Hodgkin Lymphoma
- (2015) D. Pulte et al. ONCOLOGIST
- Socioeconomic disparities in lymphoma
- (2014) C. R. Flowers et al. BLOOD
- Insurance status is related to diffuse large B-cell lymphoma survival
- (2014) Xuesong Han et al. CANCER
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
- (2014) Aaron M Newman et al. NATURE MEDICINE
- Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL
- (2012) A C Rawstron et al. LEUKEMIA
- CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
- (2011) Michael Pfreundschuh et al. LANCET ONCOLOGY
- Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
- (2008) Michael Pfreundschuh et al. LANCET ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search